Suppr超能文献

CD40抗体引发一种细胞毒性T细胞反应,这种反应可根除淋巴瘤并绕过T细胞辅助。

CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help.

作者信息

French R R, Chan H T, Tutt A L, Glennie M J

机构信息

Lymphoma Research Unit, Tenovus Laboratory, General Hospital, Southampton, UK.

出版信息

Nat Med. 1999 May;5(5):548-53. doi: 10.1038/8426.

Abstract

CD40 is essential in enabling antigen-presenting cells to process and present antigen effectively to T cells. We demonstrate here that when antibody against CD40 is used to treat mice with syngeneic lymphoma, a rapid cytotoxic T-cell response independent of T-helper cells occurs, with tenfold expansion of CD8+ T cells over a period of 5 days. This response eradicates the lymphoma and provides protection against tumor rechallenge without further antibody treatment. Thus, it seems that by treating mice with monoclonal antibody against CD40, we are immunizing against syngeneic tumors. The phenomenon proved reproducible with two antibodies against CD40 (3/23 and FGK-45) in three CD40+ lymphomas (A20, A31 and BCL1) and gave partial protection in one of two CD40- lymphomas (EL4 and Ten1). Although the nature of the target antigens on these lymphomas is unknown, CD8+ T cells recovered from responding mice showed powerful cytotoxic activity against the target B-cell lymphoma in vitro.

摘要

CD40对于使抗原呈递细胞有效地处理和呈递抗原给T细胞至关重要。我们在此证明,当用抗CD40抗体治疗患有同基因淋巴瘤的小鼠时,会发生独立于辅助性T细胞的快速细胞毒性T细胞反应,在5天内CD8 + T细胞扩增了10倍。这种反应根除了淋巴瘤,并在无需进一步抗体治疗的情况下提供了针对肿瘤再次攻击的保护作用。因此,似乎通过用抗CD40单克隆抗体治疗小鼠,我们正在针对同基因肿瘤进行免疫。在三种CD40 +淋巴瘤(A20、A31和BCL1)中,用两种抗CD40抗体(3/23和FGK-45)证明了该现象具有可重复性,并且在两种CD40-淋巴瘤(EL4和Ten1)中的一种中提供了部分保护作用。尽管这些淋巴瘤上靶抗原的性质尚不清楚,但从反应小鼠中回收的CD8 + T细胞在体外对靶B细胞淋巴瘤显示出强大的细胞毒性活性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验